Categories
Anticancer Drugs Medicine Oncology Palbociclib Pharmacology Physiotherapy

Palbociclib

In this article we will discuss about Palbociclib (Dosage Overview)

In this article, we will discuss Palbociclib (Dosage Overview). So, let’s get started.

Indications

Palbociclib (IBRANCE®) is indicated for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer in combination with:
• an aromatase inhibitor as initial endocrine-based therapy in postmenopausal women or in men; or
• fulvestrant in patients with disease progression following endocrine therapy.

Dosage

Recommended Dose and Schedule

The recommended dose of Palbociclib (IBRANCE®) is a 125 mg tablet taken orally once daily for 21 consecutive days followed by 7 days off treatment to comprise a complete cycle of 28 days. Palbociclib (IBRANCE®) tablet may be taken with or without food.

Administer the recommended dose of an aromatase inhibitor when given with Palbociclib (IBRANCE®).

When given with Palbociclib (IBRANCE®), the recommended dose of fulvestrant is 500 mg administered on Days 1, 15, 29, and once monthly thereafter.

Patients should be encouraged to take their dose of Palbociclib (IBRANCE®) at approximately the same time each day. If the patient vomits or misses a dose, an additional dose should not be taken. The next prescribed dose should be taken at the usual time.

Pre/perimenopausal women treated with the combination Palbociclib (IBRANCE®) plus fulvestrant therapy should also be treated with luteinizing hormone-releasing hormone (LHRH) agonists according to current clinical practice standards.

For men treated with combination Palbociclib (IBRANCE®) plus aromatase inhibitor therapy, consider treatment with an LHRH agonist according to current clinical practice standards.

Adverse Reactions

Most common adverse reactions (incidence ≥10%) were neutropenia,
infections, leukopenia, fatigue, nausea, stomatitis, anemia, alopecia, diarrhea, thrombocytopenia, rash, vomiting, decreased appetite, asthenia, and
pyrexia.

Leave a Reply

This site uses Akismet to reduce spam. Learn how your comment data is processed.